EUS-guided Through-the-needle Microforceps Biopsy Outcomes
How Does the EUS-guided Through-the-needle Microforceps Biopsy Improve Diagnosis of Pancreatic Cystic Lesions: A Multicenter Prospective Study
1 other identifier
observational
50
1 country
1
Brief Summary
INTRODUCTION: The diagnosis of pancreatic cystic lesions (PCLs) is increasing due to improvements of cross-sectional imaging. It is mandatory, for appropriate management, to make an accurate diagnosis and risk stratification, since some of these lesions may harbor malignancy or have potential for malignant transformation and hence surgical resection is required. Diagnostic evaluation of PCLs can be challenging, requiring a combination of different methods. Usually PCLs are been initially detected by cross-sectional imaging. However, imaging alone has not been shown to reliably identify the underlying pathology in PCLs with a high degree of accuracy. Hence, Endoscopic ultrasound with fine-needle aspiration (EUS-FNA) is routinely performed. EUS-FNA plays an important role in cyst characterization since allows morphological examination (EUS-B mode), aspiration for cytology and cyst fluid analysis for carcinoembryonic antigen (CEA), amylase and glucose levels; and allows to tissue sample in case of mural nodules o wall thickness. Even though EUS-FNA has been shown to be the test of choice for select lesions with high-risk features, has its limitations related to low sensitivity and specificity. The morphological characterization by EUS of PCL, as well as with the cross-sectional images, depends most of the time, on the subjective interpretation of the operator, which can be very difficult sometimes and depend on experience. A cyst fluid CEA cutoff of 192 ng/mL has been commonly accepted for differentiating mucinous from non-mucinous cysts. However, has the limitation of requiring at least 0.5 mL of cyst fluid for CEA analysis, has a relatively low sensitivity (75%) and specificity (84%), cannot differentiate cyst histotypes, and controversial results have been reported. Finally targeted cyst wall with the tip of the FNA needle can increase the diagnostic accuracy, yet the cytological yield with EUS-FNA remains low due to the relatively small tissue sample. Hence, diagnostic accuracy of currently available tools for evaluation of PCLs including cross-sectional imaging, EUS morphologic features, EUS-FNA for cyst fluid analysis and cytology is not perfect, leading to possible misdiagnosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 22, 2019
CompletedStudy Start
First participant enrolled
October 22, 2019
CompletedFirst Posted
Study publicly available on registry
October 25, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2022
CompletedJune 1, 2022
May 1, 2022
2.9 years
October 22, 2019
May 30, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The increment in diagnostic yield
The diagnostic performance (accuracy) of the device will be compared to standard evaluation accuracy (cross-sectional imaging and EUS-FNA with cyst fluid analysis) and finally corroborated with surgery biopsy and 12 month follow up (gold standard).
1 year
Secondary Outcomes (4)
Percentage of technical success
1 year
Percentage of clinical success
1 year
Percentage of adverse events
1 year
The inter-observer agreement
1 year
Study Arms (1)
TTNB group
Patients with PCLs suitable for biopsy.
Interventions
EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two "bites" per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology.
Eligibility Criteria
Patients with pancreatic cysts suitable for EUS TTNB with microforceps.
You may qualify if:
- Aged ≥ 18 years old patients.
- Patints that agree to participate in the study.
- PCLs ≥ 10mm, large enough to accommodate the microforceps.
- Patients with PCLs and high-risk features (cyst \> 3 cm, thickened wall, dilated pancreatic duct, mural nodules and solid component).
- New diagnosis of a PCL or interval changes in morphology on surveillance (cyst growth or high-risk features).
- Patients with PCLs and symptoms (e. g. pancreatitis, abdominal pain, obstructive jaundice).
- Patients with PCLs but without high-risk features and anxiety about the diagnosis.
You may not qualify if:
- Inability to provide informed consent for the procedure.
- Pregnancy.
- Platelet count less than 50,000/ml or International Normalized Rate (INR) \>2.
- Esophageal stricture or any pathology that does noy allows performing EUS.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institute of Gastroenterology and Advanced Endoscopy (IGEA)
BahĂa Blanca, Buenos Aires, 8000, Argentina
Related Publications (16)
Stark A, Donahue TR, Reber HA, Hines OJ. Pancreatic Cyst Disease: A Review. JAMA. 2016 May 3;315(17):1882-93. doi: 10.1001/jama.2016.4690.
PMID: 27139061RESULTLee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol. 2010 Sep;105(9):2079-84. doi: 10.1038/ajg.2010.122. Epub 2010 Mar 30.
PMID: 20354507RESULTCorrea-Gallego C, Ferrone CR, Thayer SP, Wargo JA, Warshaw AL, Fernandez-Del Castillo C. Incidental pancreatic cysts: do we really know what we are watching? Pancreatology. 2010;10(2-3):144-50. doi: 10.1159/000243733. Epub 2010 May 17.
PMID: 20484954RESULTCho CS, Russ AJ, Loeffler AG, Rettammel RJ, Oudheusden G, Winslow ER, Weber SM. Preoperative classification of pancreatic cystic neoplasms: the clinical significance of diagnostic inaccuracy. Ann Surg Oncol. 2013 Sep;20(9):3112-9. doi: 10.1245/s10434-013-2986-6. Epub 2013 Apr 18.
PMID: 23595223RESULTRogart JN, Loren DE, Singu BS, Kowalski TE. Cyst wall puncture and aspiration during EUS-guided fine needle aspiration may increase the diagnostic yield of mucinous cysts of the pancreas. J Clin Gastroenterol. 2011 Feb;45(2):164-9. doi: 10.1097/MCG.0b013e3181eed6d2.
PMID: 20818233RESULTHong SK, Loren DE, Rogart JN, Siddiqui AA, Sendecki JA, Bibbo M, Coben RM, Meckes DP, Kowalski TE. Targeted cyst wall puncture and aspiration during EUS-FNA increases the diagnostic yield of premalignant and malignant pancreatic cysts. Gastrointest Endosc. 2012 Apr;75(4):775-82. doi: 10.1016/j.gie.2011.12.015. Epub 2012 Feb 7.
PMID: 22317883RESULTAlkaade S, Chahla E, Levy M. Role of endoscopic ultrasound-guided fine-needle aspiration cytology, viscosity, and carcinoembryonic antigen in pancreatic cyst fluid. Endosc Ultrasound. 2015 Oct-Dec;4(4):299-303. doi: 10.4103/2303-9027.170417.
PMID: 26643697RESULTBrugge WR, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, del Castillo CF, Warshaw AL. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004 May;126(5):1330-6. doi: 10.1053/j.gastro.2004.02.013.
PMID: 15131794RESULTde Jong K, Poley JW, van Hooft JE, Visser M, Bruno MJ, Fockens P. Endoscopic ultrasound-guided fine-needle aspiration of pancreatic cystic lesions provides inadequate material for cytology and laboratory analysis: initial results from a prospective study. Endoscopy. 2011 Jul;43(7):585-90. doi: 10.1055/s-0030-1256440. Epub 2011 May 24.
PMID: 21611945RESULTGaddam S, Ge PS, Keach JW, Mullady D, Fukami N, Edmundowicz SA, Azar RR, Shah RJ, Murad FM, Kushnir VM, Watson RR, Ghassemi KF, Sedarat A, Komanduri S, Jaiyeola DM, Brauer BC, Yen RD, Amateau SK, Hosford L, Hollander T, Donahue TR, Schulick RD, Edil BH, McCarter M, Gajdos C, Attwell A, Muthusamy VR, Early DS, Wani S. Suboptimal accuracy of carcinoembryonic antigen in differentiation of mucinous and nonmucinous pancreatic cysts: results of a large multicenter study. Gastrointest Endosc. 2015 Dec;82(6):1060-9. doi: 10.1016/j.gie.2015.04.040. Epub 2015 Jun 12.
PMID: 26077458RESULTMittal C, Obuch JC, Hammad H, Edmundowicz SA, Wani S, Shah RJ, Brauer BC, Attwell AR, Kaplan JB, Wagh MS. Technical feasibility, diagnostic yield, and safety of microforceps biopsies during EUS evaluation of pancreatic cystic lesions (with video). Gastrointest Endosc. 2018 May;87(5):1263-1269. doi: 10.1016/j.gie.2017.12.025. Epub 2018 Jan 6.
PMID: 29309781RESULTTanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K; International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012 May-Jun;12(3):183-97. doi: 10.1016/j.pan.2012.04.004. Epub 2012 Apr 16.
PMID: 22687371RESULTScheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015 Apr;148(4):824-48.e22. doi: 10.1053/j.gastro.2015.01.014. No abstract available.
PMID: 25805376RESULTCotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. No abstract available.
PMID: 20189503RESULTCrino SF, Bernardoni L, Brozzi L, Barresi L, Malleo G, Salvia R, Frulloni L, Sina S, Parisi A, Remo A, Larghi A, Gabbrielli A, Manfrin E. Association between macroscopically visible tissue samples and diagnostic accuracy of EUS-guided through-the-needle microforceps biopsy sampling of pancreatic cystic lesions. Gastrointest Endosc. 2019 Dec;90(6):933-943. doi: 10.1016/j.gie.2019.05.009. Epub 2019 May 14.
PMID: 31100310RESULTYang D, Samarasena JB, Jamil LH, Chang KJ, Lee D, Ona MA, Lo SK, Gaddam S, Liu Q, Draganov PV. Endoscopic ultrasound-guided through-the-needle microforceps biopsy in the evaluation of pancreatic cystic lesions: a multicenter study. Endosc Int Open. 2018 Dec;6(12):E1423-E1430. doi: 10.1055/a-0770-2700. Epub 2018 Dec 5.
PMID: 30574535RESULT
Biospecimen
Samples of cyst wall
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Manuel Valero, MD
Institute of Gastroenterology and Advanced Endoscopy (IGEA)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 22, 2019
First Posted
October 25, 2019
Study Start
October 22, 2019
Primary Completion
October 1, 2022
Study Completion
November 1, 2022
Last Updated
June 1, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share